Planta Med 2002; 68(7): 577-580
DOI: 10.1055/s-2002-32908
Rapid Communication
© Georg Thieme Verlag Stuttgart · New York

Rutin is Essential for the Antidepressant Activity of Hypericum perforatum Extracts in the Forced Swimming Test

Michael Nöldner1 , Karl Schötz1
  • 1Department of Pharmacology and Phytochemistry, Dr. Willmar Schwabe Pharmaceuticals, Karlsruhe, Germany
Further Information

Publication History

Received: January 10, 2002

Accepted: March 22, 2002

Publication Date:
22 July 2002 (online)

Abstract

It has been shown that aqueous alcoholic extracts of Hypericum perforatum (St. John’s wort) are active in the forced swimming test (FST), an animal model for antidepressant activity. In this study, a series of ethanolic and methanolic extracts were investigated and, in almost all cases, the extracts showed strong activity. Only one methanolic research extract had no effect in the in vivo pharmacological experiments. Analytical characterisation using HPLC showed that the inactive extract had a reduced level of the diglycoside flavonoid rutin. Addition of rutin to the inactive extract, to produce a concentration within the normal range, resulted in a strong pharmacological effect comparable to that of the other extracts. First experiments suggest that this re-activation is not dose-dependent, indicating that rutin must be present above a threshold limit. It therefore appears vital that extracts of St. John’s wort which are designed for the therapy of depressive disorders should be manufactured using plant material with sufficient amounts of rutin.

References

  • 1 Phillip M, Kohnen R, Hiller K O. Hypericum extracts versus imipramin or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks.  British Medical Journal. 1999;  319 1534-8
  • 2 Brenner R, Azbel V, Madhusoodanan S, Pawlowska M. Camparison of an extract of Hypericum (LI 160) and sertraline in the treatment of depression: A double blind, randomized pilot-study.  Clinical Therapy. 2000;  22 411-9
  • 3 Schrader E. Equivalence of St. John’s wort extract (ZE 117) and fluoxetine: a randomized, controlled study in mild-moderate depression.  International Clinical Psychopharmacology. 2000;  15 61-8
  • 4 Erdelmeyer C AJ. Hyperforin, possibly the major non-nitrogenous secondary metabolite of Hypericum perforatum L.  Pharmacopsychiatry. 1998;  31 (Supplement) 2-6
  • 5 Butterweck V, Wall A, Lieflaender-Wulf U, Winterhoff H, Nahrstedt A. Effects of the total extract and fractions of Hypericum perforatum in animal assays for antidepressant activity.  Pharmacopsychiatry. 1997;  30 (Supplement) 117-24
  • 6 Chatterjee S S, Nöldner M, Koch E, Erdelmeier C AJ. Antidepressant activity of Hypericum perforatum and hyperforin: the neglected possibility.  Pharmacopsychiatry. 1998;  31 (Supplement) 7-15
  • 7 Battacharya S K, Chakrabarti A, Chatterjee S S. Activity profiles of two hyperforin-containing Hypericum extracts in behavioral models.  Pharmacopsychiatry. 1998;  31 (Supplement) 22-9
  • 8 Butterweck V, Petereit F, Winterhoff H, Nahrstedt A. Solubilized hypericin and pseudohypericin from Hypericum perforatum exert antidepressant activity in the forced swimming test.  Planta Medica. 1998;  64 291-4
  • 9 Butterweck V, Jürgenliemk G, Nahrstedt A, Winterhoff H. Flavonoids from Hypericum perforatum show antidepressant activity in the forced swimming test.  Planta Medica. 2000;  66 3-6
  • 10 Butterweck V, Korte B, Winterhoff H. Pharmacological and endocrine effects of Hypericum perforatum and hypericin after repeated treatment.  Pharmacopsychiatry. 2001;  34 (Supplement 1) S2-7
  • 11 Porsolt R, Anton G, Blavet N, Jalfre M. Behavioral despair in rats: A new model sensitive to antidepressant treatments.  European Journal of Pharmacology. 1978;  47 379-91
  • 12 Hölzl J, Ostrowksi E. Johanniskraut (Hypericum perforatum L.) HPLC-Analyse der wichtigen Inhaltsstoffe und deren Variabilität in einer Population.  Deutsche Apotheker Zeitung. 1987;  127 1227-9
  • 13 Brolis M, Gabetta B, Fuzatti N, Pace R, Panzeri F, Peterlongo F. Identification by high-performance liquid chromatography-diode array detection-mass spectroscopy and quantification by high-performance liquid chromatography-UV absorption detection of active constituents of Hypericum perforatum .  Journal of Chromatography A. 1998;  825 9-16
  • 14 Jürgenliemk G, Nahrstedt A. Phenolic compounds from Hypericum perforatum L.  Planta Medica. 2002;  68 88-91
  • 15 Tekel’ova D, Repcak M, Zemkova E, Toth J. Quantitative changes of dianthrones, hyperforin and flavonoids content in the flower ontogenesis of Hypericum perforatum .  Planta Medica. 2000;  66 778-80
  • 16 Martonfi P, Repcak M, Ciccarelli D, Garbari F. Hypericum perforatum L. - chemotype without rutin in Italy.  Biochemical Systematics and Ecology. 2001;  29 659-61
  • 17 Umek A, Kreft S, Kartnig D, Heydel B. Quantitative phytochemical analyses of six Hypericum species growing in Slovenia.  Planta Medica. 1999;  65 388-90
  • 18 Spahn-Langguth H, Langguth P. Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinol.  European Journal of Pharmaceutical Sciences. 2001;  12 361-7
  • 19 Kubinova R, Machala M, Minksova K, Neca J. Suchy V. Chemoprotective activity of boldine: modulation of drug-metabolizing enzymes.  Pharmazie. 2001;  56 242-3
  • 20 Obermeier M T, White R E, Young C S. Effects of bioflavonoids on hepatic P450 activities.  Xenobiotica. 1995;  25 575-84
  • 21 Holm S. A simple sequentially rejective multiple test procedure.  Scandinavian Journal of Statistics. 1979;  6 65-70

Dr. Michael Nöldner

Dr. Willmar Schwabe GmbH

Dept. of Pharmacology

Willmar Schwabe Straße 4


76227 Karlsruhe

Germany

Email: michael-noeldner@schwabe.de

    >